Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind trial of ustekinumab in Takayasu arteritis
jRCT2061210007Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Takayasu arteritis (TAK) comparing Ustekinumab arm with Placebo arm (2 arms). Primary endpoint: Time to relapse through the end of double-blind period. Started Oct 2021; status: completed.
02
Drugs
ustekinumab
03
Conditions
Takayasu arteritis (TAK)
Beyond the preview
Go deeper on jRCT2061210007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061210007.